8-K: AEON Biopharma Deleveraging via Daewoong Debt-to-Equity Exchange

AEON Biopharma announced a definitive agreement with Daewoong Pharmaceutical to exchange $15 million in convertible notes for new equity, a $1.5 million new note, and warrants, significantly deleveraging the company.

Summary

• AEON Biopharma and Daewoong Pharmaceutical Co., Ltd. executed an Exchange Agreement to convert $15 million of existing senior secured convertible notes plus accrued interest.
• The exchange will result in Daewoong receiving approximately 23.1 million newly issued shares of Common Stock and/or Pre-Funded Warrants (to maintain a 49.99% beneficial ownership limit).
• Daewoong will also receive a new senior secured convertible note for $1.5 million, maturing on April 12, 2030, with an annual interest rate of 15.79%.
• Additionally, Daewoong will receive warrants to purchase up to 8 million shares of Common Stock at an exercise price of $1.09392 per share, exercisable for cash over five years.
• The transaction is subject to stockholder approval in accordance with NYSE American rules and other customary closing conditions.
• The company expects the exchange to eliminate over 90% of its outstanding debt.

Sentiment

Score: 7

Explanation: The filing outlines a significant debt-to-equity exchange that substantially reduces the company's debt burden and strengthens a key strategic partnership. While there is considerable dilution and a high interest rate on the remaining debt, the overall financial restructuring is presented as a positive step for future development and market strategy. The potential for future cash from warrant exercise also adds a positive element.

Positives

• Elimination of more than 90% of outstanding debt, significantly improving the company's capital structure.
• Strengthens Daewoong's long-term strategic alignment with AEON Biopharma and its stockholders.
• Potential for over $8 million in additional cash proceeds if the cash-exercise warrants are fully exercised.
• Daewoong's continued investment and board representation signal confidence.
• The new convertible note has a lower principal amount ($1.5M vs $15M original).

Negatives

• Issuance of a significant number of new shares (estimated 23.1 million) and warrants could lead to substantial dilution for existing shareholders.
• The new convertible note still carries a high interest rate of 15.79% per annum.
• The transaction is subject to stockholder approval, introducing a contingency.
• Daewoong's beneficial ownership limit of 49.99% is high, indicating significant control potential.
• The company cannot prepay the new convertible note prior to maturity.

Risks

• Inability to close the proposed Exchange due to failure to obtain stockholder approval.
• Failure to satisfy other conditions to closing of the proposed Exchange.
• Risks and uncertainties set forth in the company's filings with the SEC from time to time.
• Potential for dilution from the issuance of new equity and warrants.
• The company's ability to maintain listing on NYSE American or another Trading Market.

Future Outlook

The company anticipates that the deleveraging resulting from this exchange will set the stage for continued progress in its ABP-450 biosimilar strategy in 2026. The successful consummation of the exchange is contingent on stockholder approval and other closing conditions.

Management Comments

• "We are pleased to report the signing of definitive documentation for our exchange of Daewoong’s existing AEON-issued debt."
• "While the transaction remains subject to a shareholder vote, this is an important step forward in deleveraging the company and we believe sets the stage for continued progress for our ABP-450 biosimilar strategy in 2026."

Industry Context

The U.S. therapeutic neurotoxin market, exceeding $3.0 billion annually, presents a significant opportunity for biosimilar entry. AEON Biopharma's ABP-450, a biosimilar to BOTOX, positions the company to capitalize on this market. This debt-to-equity exchange strengthens AEON's financial position, potentially enabling it to better compete in this high-value market against established players.

Comparison to Industry Standards

• The high interest rate of 15.79% on the new convertible note, and a default rate of 25%, suggests a higher risk profile compared to typical corporate debt for more established pharmaceutical companies.
• The significant equity issuance and warrants to a single strategic partner (Daewoong) with a 49.99% beneficial ownership limit is a common mechanism in early-stage biotech for securing funding and strategic alignment, but it also indicates a substantial reliance on that partner.
• The focus on a biosimilar (ABP-450 to BOTOX) aligns with a growing industry trend of developing lower-cost alternatives to high-priced biologics, a strategy employed by companies like Amgen (with Amjevita, a Humira biosimilar) or Pfizer (with Inflectra, a Remicade biosimilar).
• The requirement for stockholder approval for such a significant transaction is standard corporate governance for public companies, especially when it involves substantial equity dilution or changes in control.

Management Changes

Corporate Governance

Related Party Transactions

• The Exchange Agreement is between AEON Biopharma, Inc., AEON Biopharma Sub, Inc., and Daewoong Pharmaceutical Co., Ltd. Daewoong was the sole holder of the original $15 million convertible notes and is a strategic partner (manufacturer of ABP-450).
• The transaction involves the exchange of existing debt held by Daewoong for new equity, a new convertible note, and warrants, as well as a board nomination right for Daewoong.
• The Fifth Amendment to the License and Supply Agreement between the Company and Daewoong is also part of the Transaction Documents.

Stakeholder Impact

• Shareholders: Significant dilution from the issuance of approximately 23.1 million new shares and 8 million warrants to Daewoong. However, the deleveraging could improve the company's financial stability and long-term prospects.
• Creditors (excluding Daewoong): The elimination of over 90% of outstanding debt improves the company's overall credit profile. The new $1.5 million note to Daewoong is senior secured.
• Daewoong Pharmaceutical: Strengthens its strategic alignment and ownership stake in AEON Biopharma, gaining board representation and significant control over key development decisions. Converts a large portion of debt into equity, aligning its interests more closely with AEON's long-term success.
• Employees: Improved financial stability could provide greater job security and resources for ongoing projects.
• Customers/Patients: Continued progress on the ABP-450 biosimilar strategy could eventually lead to a new therapeutic option in the neurotoxin market.

Next Steps

• Obtain stockholder approval for the Exchange.
• Satisfy other customary closing conditions for the Exchange.
• File a shelf Registration Statement on Form S-1 (or short-form equivalent) with the SEC to register the resale of the Registerable Securities.
• Nominate one designee of Daewoong (currently Seongsoo Park) to the company's board of directors as a Class III director at the 2026 annual meeting of stockholders.
• Continue progress on the ABP-450 biosimilar strategy in 2026.

Key Dates

Recommendation

The transaction significantly deleverages AEON Biopharma, which is a positive for financial stability and long-term viability. The strengthened strategic alignment with Daewoong, a key partner and manufacturer of ABP-450, is also beneficial for the biosimilar strategy. However, the substantial equity dilution from the issuance of new shares and warrants, coupled with the high interest rate on the remaining convertible note, presents a mixed picture. The stock is likely to experience volatility due to the dilution and the need for shareholder approval. A 'hold' recommendation is appropriate as investors should monitor the shareholder vote outcome and the company's execution on its ABP-450 strategy post-exchange before making further investment decisions.

Keywords

AEON Biopharma, Daewoong Pharmaceutical, Debt Exchange, Convertible Notes, Equity Financing, Warrants, ABP-450, Biosimilar, BOTOX, Deleveraging, Capital Structure, Shareholder Approval, Biopharmaceutical, NYSE American